Asia spectacular rise create serious challenges
Beijing establishes medical dispute resolution committee
China Tops India on World Diabetes Ladder as Boom Spurs Obesity
China Sky One to launch 13 products in six months
Dragon Pharmaceuticals Inc. (DRUG) to Go Private for $0.82/Share
MDRNA, Inc. announced an RNAi cancer collaboration with AstraZeneca Investment (China) Company that is being carried out at AstraZeneca Innovation Centre in Shanghai. MDRNAâ€™s RNA interference technology combines two proteins to simultaneously inhibit two processes. In the AstraZeneca collaboration, the formulation is being tested as a treatment for liver cancer.
Milestone Scientific expects SFDA approval of its dental anaesthesia medical device, the STA Systemâ„¢, within three to four months . Once the approval is granted, Milestone will begin shipments to Sinopharm, its marketing partner that is also helping with the regulatory process. Milestone and Sinopharm signed a three-year blanket purchase order late last year. The STA System takes the place of a syringe to deliver anaesthesia painlessly to a single tooth.
New national drug price list to include all NRDL and NEDL products
OriGene Technologies, Inc., a gene-centric life sciences company based in Maryland, completed a $16 million Series B financing, which it will use to continue building its TrueMABâ„¢ collection of monoclonal antibodies (see story). In February 2009, OriGene purchased the assets of Shenzhen P&A Biotech, a company that provides monoclonal antibodies. OriGene said it would use its new China monoclonal antibody production facility to produce several thousand high quality monoclonal antibodies per year.
Qiagen establishes sponsored professorship in USTC
Scientists make genetically-modified cow with high Omega-3 fatty acid level
Simcere Pharmaceutical Group has successfully completed a Phase IV clinical trial of Endostar, its patented cancer drug, in patients with non-small cell lung cancer (NSCLC). Endostar, a Class-1 drug with an anti-angiogenesis mechanism, was approved by the SFDA in 2005 to treat NSCLC. Simcere said the drug, which was administered as an adjunct to chemotherapy, significantly improved outcomes without causing additional adverse effects.
Sinovac Biotech Ltd. Enters Exclusive Supply and Distribution Agreements with Parenteral Biotech Ltd. for India
Wuxi MTLH Biotechnology Co., a company founded in December 2007, has sold the China rights for its lead molecule, an anti-cancer drug, to Shanghai The First Biochemical Pharmaceutical Co. Ltd., a subsidiary of Shanghai Pharmaceutical Group. MTLH-001 is a peptide PDGFR antagonist in pre-clinical development. SBPC will co-develop the product with MTLH according to FDA standards, helping MTLH to launch the drug globally.